Close

Needham & Company Q2 Preview on Cubist Pharmaceuticals (CBST); Cubicin Sales Estimate is $195M

July 18, 2012 10:50 AM EDT
Get Alerts CBST Hot Sheet
Price: $101.94 --0%

Rating Summary:
    6 Buy, 13 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Cubist Pharmaceuticals (NASDAQ: CBST).

Analyst, Alan Carr, said, "Cubist is scheduled to announce 2Q12 financial results on 7/19/12. Our U.S. 2Q12 Cubicin sales estimate is $195M. The company reported $184.7M in 1Q12 U.S. Cubicin sales (+20.2% y/y). Outpatient use continues to be a key driver of growth. Current 2012 U.S. Cubicin sales guidance is $790-815M."

"We are neutral on the stock, awaiting further progression of the company pipeline.
Cubist ended 1Q12 with $862M in cash, down from $868M at YE11 due in part to
payments to licensor Lilly (NYSE: LLY) and Calixa shareholders."

For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.

Shares of Cubist Pharmaceuticals closed at $41.51 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company, Earnings